What percentage of patients taking FGAs, especially low potency, experience weight gain?

What percentage of patients taking FGAs, especially low potency, experience weight gain?

• A. 10%
• B. 60%
• C. 40%
• D. 20%

Answer: (C)

Weight gain risk with first-generation antipsychotics, especially the low-potency ones, is driven by histamine H1 receptor blockade that increases appetite and can lead to higher caloric intake. Because this effect occurs in a sizable portion of patients but not everyone, about forty percent experience weight gain during treatment with FGAs. This makes forty percent the best estimate among the given options, reflecting a common but not universal side effect profile for these drugs. Keep in mind that higher-potency FGAs tend to have a lower risk, while second-generation antipsychotics often show different weight gain patterns depending on the agent. Monitoring weight and metabolic health is important when starting or adjusting these medications.

Weight gain risk with first-generation antipsychotics, especially the low-potency ones, is driven by histamine H1 receptor blockade that increases appetite and can lead to higher caloric intake. Because this effect occurs in a sizable portion of patients but not everyone, about forty percent experience weight gain during treatment with FGAs. This makes forty percent the best estimate among the given options, reflecting a common but not universal side effect profile for these drugs. Keep in mind that higher-potency FGAs tend to have a lower risk, while second-generation antipsychotics often show different weight gain patterns depending on the agent. Monitoring weight and metabolic health is important when starting or adjusting these medications.